

---

Product Manual


# QuickTiter™ Hepatitis B Core Antigen (HBVcAg) ELISA Kit

## Catalog Numbers

VPK-150	96 assays
VPK-150-5	5 x 96 assays

**FOR RESEARCH USE ONLY**  
**Not for use in diagnostic procedures**

---



**CELL BIOLABS, INC.**  
*Creating Solutions for Life Science Research*

## **Introduction**

Hepatitis B is an infection of the liver caused by the hepatitis B virus. HBV is transmitted by exposure to infectious blood or body fluids (e.g. saliva, semen, urine); forms of transmission include unprotected sexual activity, blood transfusion, mother-to-infant transmission, or consuming contaminated food/water. The acute illness causes liver inflammation, vomiting and jaundice, while chronic HBV infection often leads to liver cirrhosis and cancer.

Roughly one third of the world's population have been infected with hepatitis B virus. 5-10% of adults and 90% of babies who have been infected will have the virus for the rest of their lives. The infection is preventable by vaccination.

Diagnosis of chronic hepatitis B virus (HBV) infection has long been based on HBV serology and measurement of hepatocytic enzymes. With the development of therapies for chronic HBV infection, including interferon and lamivudine, quantitative detection of HBV has been used increasingly as the most important marker for monitoring HBV replication activity, disease progression, and assessing antiviral treatment. Several assays for the quantitative measurement of HBV DNA have been developed, such as PCR-based nucleic acid amplification assays. However, these methods tend to be cumbersome and expensive.

Cell Biolabs' QuickTiter™ HBV Core Antigen ELISA Kit is an enzyme immunoassay developed for detection and quantitation of the HBV core protein. The kit has detection sensitivity limit of 1 ng /mL HBcAg. Each kit provides sufficient reagents to perform up to 96 assays including standard curve and HBV samples.

## **Assay Principle**

An anti-HBVcAg monoclonal coating antibody is adsorbed onto a microtiter plate. HBV core antigen present in the sample or standard binds to the antibodies adsorbed on the plate; a FITC-conjugated mouse anti-HBVcAg antibody is added and binds to the antigen captured by the first antibody.

Following incubation and wash steps, a HRP-conjugated mouse anti-FITC antibody is added and binds to the FITC conjugated anti-HBVcAg. Unbound HRP-conjugated mouse anti-FITC antibody is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

A colored product is formed in proportion to the amount of HBV core antigen present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from recombinant HBV core antigen and sample concentration is then determined.

## **Related Products**

1. VPK-151: QuickTiter™ Hepatitis C Core Antigen (HCcAg) ELISA Kit
2. VPK-108-H: QuickTiter™ Lentivirus Quantitation Kit (HIV-1 p24 ELISA)
3. VPK-107: QuickTiter™ Lentivirus Titer Kit (Lentivirus-Associated HIV p24)
4. VPK-112: QuickTiter™ Lentivirus Quantitation Kit
5. LTV-200: ViraDuctin™ Lentivirus Transduction Kit

## **Kit Components**

### **Box 1 (shipped at room temperature)**

1. Anti-HBVcAg Antibody Coated Plate (Part No. 315001): One strip well 96-well plate.
2. FITC-Conjugated Anti-HBVcAg Monoclonal Antibody (Part No. 315002): One 20  $\mu$ L vial.
3. HRP-Conjugated Anti-FITC Monoclonal Antibody (Part No. 310811): One 20  $\mu$ L vial.
4. Assay Diluent (Part No. 310804): One 50 mL bottle.
5. Triton X-100 Solution (Part No. 310805): One 15 mL bottle containing 5% Triton X-100 in TBS.
6. 10X Wash Buffer (Part No. 310806): One 100 mL bottle.
7. Substrate Solution (Part No. 310807): One 12 mL amber bottle.
8. Stop Solution (Part. No. 310808): One 12 mL bottle.

### **Box 2 (shipped on blue ice packs)**

1. Recombinant HBVcAg Standard (Part No. 315003): One 100  $\mu$ L vial of 10  $\mu$ g/mL recombinant HBV Core Antigen in PBS containing BSA.

## **Materials Not Supplied**

1. HBV Sample: purified virus or unpurified viral supernatant
2. Cell Culture Centrifuge
3. 0.45  $\mu$ m filter
4. Microplate reader capable of reading at 450 nm (620 nm as optional reference wave length)

## **Storage**

Upon receiving, aliquot and store recombinant HBVcAg Standard at -20°C and avoid freeze/thaw. Store all other components at 4°C.

## **Safety Considerations**

Remember that your lentiviral samples contain infectious viruses before inactivation; you must follow the recommended NIH guidelines for all materials containing infectious organisms.

## **Preparation of Reagents**

- 1X Wash Buffer: Dilute the 10X Wash Buffer Concentrate to 1X with deionized water. Stir to homogeneity.
- FITC-Conjugated Anti-HBVcAg Monoclonal Antibody and HRP-Conjugated Anti-FITC Monoclonal Antibody: Immediately before use dilute the FITC-conjugated antibody 1:1000 and HRP-conjugated antibody 1:1000 with Assay Diluent. Do not store diluted solutions.

## **Preparation of Standard Curve**

1. Prepare a dilution series of Recombinant HBVcAg Standard in the concentration range of 100 ng/mL – 1 ng/mL by diluting the stock solution in Assay Diluent (Table 1).

<b>Standard Tubes</b>	<b>HBVcAg Standard (μL)</b>	<b>Assay Diluent (μL)</b>	<b>HBVcAg (ng/mL)</b>
1	10	990	100
2	500 of Tube #1	500	50
3	500 of Tube #2	500	25
4	500 of Tube #3	500	12.5
5	500 of Tube #4	500	6.25
6	500 of Tube #5	500	3.125
7	500 of Tube #6	500	1.5625
8	0	500	0

**Table 1. Preparation of HBVcAg Standard**

2. Transfer 225μL of each dilution to a microcentrifuge tube containing 25 μL of Triton X-100 Solution. Perform the assay as described in Assay Instructions.

## **HBV Sample Dilution and Inactivation**

1. (Optional) Dilute HBV sample in culture medium. Include culture medium as a negative control.
2. Transfer 225 μL of each sample to a microcentrifuge tube containing 25 μL of Triton X-100 Solution, Vortex well.
3. Incubate 30 minutes at 37°C.

*Note: For samples that contain antibodies, release HBVcAg from the virions by incubating samples at 56°C for 30 min.*


## **Assay Protocol**

1. Prepare and mix all reagents thoroughly before use.
2. Each HBV sample, HBVcAg standard, blank, and control medium should be assayed in duplicate.
3. Add 100 μL of inactivated sample or HBVcAg standard to Anti-HBVcAg Antibody Coated Plate.
4. Cover with a Plate Cover and incubate at 37°C for 2 hours.
5. Remove plate cover and empty wells. Wash microwell strips 5 times with 250 μL 1X Wash Buffer per well with thorough aspiration between each wash. After the last wash, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess 1X Wash Buffer.
6. Add 100 μL of the diluted FITC-Conjugated Anti-HBVcAg Monoclonal Antibody to each well.
7. Cover with a plate cover and incubate at room temperature for 1 hour on an orbital shaker.

8. Remove plate cover and empty wells. Wash the strip wells 5 times according to step 5 above.
9. Add 100  $\mu$ L of the diluted HRP-Conjugated Anti-FITC Monoclonal Antibody to all wells.
10. Cover with a plate cover and incubate at room temperature for 1 hour on an orbital shaker.
11. Remove plate cover and empty wells. Wash microwell strips 5 times according to step 5 above.  
Proceed immediately to the next step.
12. Warm Substrate Solution to room temperature. Add 100  $\mu$ L of Substrate Solution to each well, including the blank wells. Incubate at room temperature on an orbital shaker. Actual incubation time may vary from 5-20 minutes.  
*Note: Watch plate carefully; if color changes rapidly, the reaction may need to be stopped sooner to prevent saturation.*
13. Stop the enzyme reaction by adding 100  $\mu$ L of Stop Solution into each well, including the blank wells. Results should be read immediately (color will fade over time).
14. Read absorbance of each microwell on a spectrophotometer using 450 nm as the primary wave length.

### **Example of Results**

The following figures demonstrate typical HBVcAg ELISA results. One should use the data below for reference only. This data should not be used to interpret actual results.



**Figure 1: HBV Core Antigen ELISA Standard Curve**

### **References**

1. Bottcher, B., S. A. Wynne, and R. A. Crowther (1997) *Nature* 386:88-91. 4
2. Bredehorst, R., H. von Wulffen, and C. Granato (1985) *J. Clin. Microbiol.* 21:593-598. 5
3. Kimura, T., A. Rokuhara, Y. Sakamoto, S. Yagi, E. Tanaka, K. Kiyosawa, and N. Maki (2002) *J. Clin. Microbiol.* 40:439-445. 15
4. Usuda, S., H. Okamoto, F. Tsuda, T. Tanaka, Y. Miyakawa, and M. Mayumi (1998) *J. Virol. Methods* 72:95-103. 30

### **Recent Product Citations**

1. Kawase, S. et al. (2026). Development of a Novel Human Hepatoma Cell Line Supporting the Replication of a Recombinant HBV Genome with a Reporter Gene. *Viruses*. **18**(2):187. doi: 10.3390/v18020187.
2. Zahir, J. et al. (2024). Comprehensive Assessment of Replication Dynamics and Characteristics in Wild Type and Corresponding Defective HBV DNA Strains. *IJBR*. **2**(02):747-755. doi: 10.70749/ijbr.v2i02.255.
3. Miyakawa, K. et al. (2022). Galectin-9 restricts hepatitis B virus replication via p62/SQSTM1-mediated selective autophagy of viral core proteins. *Nat Commun*. **13**(1):531. doi: 10.1038/s41467-022-28171-5.

4. Domfeh, S.A. et al. (2021). Cryptolepine and Nibima inhibit hepatitis B virus replication. *Sci Afr.* doi: 10.1016/j.sciaf.2021.e00942.
5. Kong, L. et al. (2021). The synthetic opioid fentanyl enhances viral replication in vitro. *PLoS One.* **16**(4):e0249581. doi: 10.1371/journal.pone.0249581.
6. Akahori, Y. et al. (2020). Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes. *Sci Rep.* **10**(1):21718. doi: 10.1038/s41598-020-78655-x.
7. Peiffer, K.H. et al. (2020). Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. *JCI Insight.* doi: 10.1172/jci.insight.135833.
8. Jiang, B. et al. (2020). The N-Terminus Makes the Difference: Impact of Genotype-Specific Disparities in the N-Terminal Part of The Hepatitis B Virus Large Surface Protein on Morphogenesis of Viral and Subviral Particles. *Cells.* **9**(8):E1898. doi: 10.3390/cells9081898.
9. Colant, N. et al. (2020). A rational approach to improving titer in E. coli-based cell-free protein synthesis reactions. *Biotechnol Prog.* doi: 10.1002/btpr.3062.
10. Jiang, B. et al. (2019). Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant. *Aliment Pharmacol Ther.* doi: 10.1111/apt.15381.
11. Biswas, B. et al. (2017). A G-quadruplex motif in an envelope gene promoter regulates transcription and virion secretion in HBV genotype B. *Nucleic Acids Res.* **45**(19):11268-11280. doi: 10.1093/nar/gkx823.

## **Warranty**

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

## **Contact Information**

Cell Biolabs, Inc.  
5628 Copley Drive  
San Diego, CA 92111  
Worldwide: +1 858-271-6500  
USA Toll-Free: 1-888-CBL-0505  
E-mail: [tech@cellbiolabs.com](mailto:tech@cellbiolabs.com)  
[www.cellbiolabs.com](http://www.cellbiolabs.com)

©2010-2026: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.